Form 4: Elanco Animal Health CEO Jeffrey Simmons Reports Acquisition of Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units on October 4, 2024.

Summary

• On October 4, 2024, Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., acquired 188.8977 deferred stock units.
• These deferred stock units represent the right to receive one share of Elanco common stock or the cash equivalent.
• The price of the transaction was $14.66 per unit.
• Following the transaction, Simmons directly owns 3,693.039 shares of Elanco common stock.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year according to the Executive Deferral and Stock Match Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing an executive's compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The CEO's acquisition of deferred stock units could be interpreted as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year in accordance with the Executive Deferral and Stock Match Plan.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's prospects.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects changes in the CEO's holdings.
• Employees may be interested in the details of the Executive Deferral and Stock Match Plan.

Key Dates